- Home
- PRT vs LTRN Comparison
PRT vs LTRN Comparison
Compare PRT & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | LTRN |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9M | 38.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRT | LTRN |
|---|---|---|
| Price | $3.46 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 55.5K | 55.0K |
| Earning Date | 03-27-2026 | 03-26-2026 |
| Dividend Yield | ★ 12.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $6,009,225.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.61 | $2.53 |
| 52 Week High | $4.63 | $5.74 |
Technical Indicators
Market Signals| Indicator | PRT | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 39.91 |
| Support Level | $3.29 | $2.63 |
| Resistance Level | $3.75 | $2.98 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 10.87 | 28.38 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.